List of Excipients in Branded Drug IMATINIB

« Back to Dashboard

Generic Drugs Containing IMATINIB

Company	Ingredient	NDC	Excipient
DrReddy's Laboratories Inc	imatinib	43598-344	ANHYDROUS LACTOSE
DrReddy's Laboratories Inc	imatinib	43598-344	CELLULOSE, MICROCRYSTALLINE
DrReddy's Laboratories Inc	imatinib	43598-344	CROSPOVIDONE
DrReddy's Laboratories Inc	imatinib	43598-344	FERRIC OXIDE RED

What are the Most Frequently-Used Excipients in IMATINIB?

# Of NDCs	Excipient
1	ANHYDROUS LACTOSE
1	CELLULOSE, MICROCRYSTALLINE
1	CROSPOVIDONE
1	FERRIC OXIDE RED

Imatinib Excipient Strategy and Commercial Opportunities

Last updated: September 30, 2026

Imatinib is a mature, high-volume small-molecule oncology product with extensive generic competition. The strongest excipient opportunities are not in basic tablet manufacture, where standard compositions are established, but in pediatric oral liquids, taste-masked dispersible systems, lower-cost robust tablets, fixed-dose combinations, and excipient-enabled global products. Imatinib is marketed primarily as imatinib mesylate, with Gleevec as the originator brand and multiple FDA-approved generic tablets.

What is the current FDA status of imatinib?

Imatinib is FDA-approved for chronic myeloid leukemia, gastrointestinal stromal tumors and several other malignancies driven by BCR-ABL, KIT or PDGFRA signaling. The reference product is Gleevec, manufactured by Novartis.

Attribute	Imatinib status
Active ingredient	Imatinib mesylate
Reference product	Gleevec
Primary dosage form	Film-coated tablet
FDA approval	New drug application for Gleevec approved in 2001
Main strengths	100 mg and 400 mg tablets
Administration	Oral, with food and a large glass of water
Regulatory class	Small molecule
Generic pathway	ANDA, generally requiring bioequivalence
Biosimilar pathway	Not applicable
Major uses	CML, GIST, Ph-positive acute lymphoblastic leukemia and other kinase-driven cancers

The Gleevec label states that tablets contain imatinib mesylate equivalent to 100 mg or 400 mg of imatinib. The listed inactive ingredients include microcrystalline cellulose, crospovidone, hypromellose, colloidal silicon dioxide, magnesium stearate, talc and colorants, with formulation differences by strength and product presentation (Novartis Pharmaceuticals Corporation, 2023).

When did imatinib lose market exclusivity?

The principal U.S. compound patent for imatinib was U.S. Patent No. 5,521,184, assigned to Ciba-Geigy, later part of Novartis. The patent issued in 1996 and covered phenylaminopyrimidine compounds, including imatinib. Its effective U.S. protection ended in the mid-2010s after patent-term adjustment and pediatric exclusivity considerations.

FDA-approved generic imatinib products began entering the U.S. market in 2016. Teva Pharmaceuticals received approval for imatinib mesylate tablets in February 2016, with other manufacturers following through the year. Generic entry materially reduced the commercial value of the Gleevec brand while expanding access to lower-cost product.

Imatinib exclusivity timeline

Event	Approximate date
U.S. compound patent issued	1996
Gleevec first FDA approval	2001
Expanded oncology indications	2002-2010
U.S. pediatric exclusivity period	Extended effective protection into 2016
First major U.S. generic approvals	2016
Broad generic competition	2016 onward

The commercial opportunity has therefore shifted from originator exclusivity to manufacturing efficiency, differentiated delivery, regional supply and excipient-enabled product improvements.

What patents protect imatinib products?

The core compound patent no longer creates a material barrier to conventional generic imatinib tablets in the United States. Remaining patent value depends on jurisdiction, specific formulation claims, manufacturing claims and method-of-use claims.

Patent category	Commercial relevance
Core compound patents	Historically protected imatinib and related kinase inhibitors; largely expired in major markets
Salt and crystal-form patents	May affect specific solid-state forms, processes or jurisdictions
Formulation patents	Potentially relevant to dispersible tablets, oral liquids, modified release and taste masking
Method-of-use patents	May cover specific cancers, dosing schedules or patient populations, subject to validity and listing status
Manufacturing patents	Can protect crystallization, impurity control, particle engineering or high-purity processes
Pediatric formulations	Potential opportunity where a product improves administration or dosing flexibility

A conventional immediate-release imatinib tablet has limited freedom to claim broad composition-of-matter protection because the active ingredient is long established. New intellectual property is more likely to arise from excipient ratios, multiparticulate architecture, taste-masking systems, reconstitution stability, dissolution control, packaging and manufacturing controls.

What excipients are used in Gleevec tablets?

The Gleevec tablet is a conventional film-coated solid oral dosage form. The excipient system supports powder flow, compression, disintegration, coating integrity and dose uniformity.

Excipient class	Representative excipient	Function
Diluent	Microcrystalline cellulose	Compressibility and tablet bulk
Disintegrant	Crospovidone	Rapid tablet breakup
Binder or film former	Hypromellose	Coating and structural support
Glidant	Colloidal silicon dioxide	Flow and processing
Lubricant	Magnesium stearate	Ejection from tablet tooling
Coating aid	Talc	Anti-tacking and coating performance
Colorant	Iron oxides or other approved colorants	Product identification and appearance

The originator formulation establishes a regulatory benchmark, but it does not force generic manufacturers to use the same excipients. An ANDA applicant can use a different qualitative and quantitative composition if the product satisfies pharmaceutical equivalence, bioequivalence, quality and labeling requirements.

How should manufacturers design an imatinib excipient system?

Imatinib formulation development should begin with the target product profile rather than direct replication of Gleevec. The most commercially efficient design for a standard generic is a low-cost immediate-release tablet using commonly qualified excipients and a manufacturing process that controls dissolution across scale.

Immediate-release tablets

A practical generic tablet platform may use:

• Microcrystalline cellulose or a co-processed filler for compression.
• Crospovidone or sodium starch glycolate for disintegration.
• Povidone or hydroxypropyl cellulose if additional granule strength is needed.
• Colloidal silicon dioxide for flow improvement.
• Magnesium stearate at a controlled level to prevent over-lubrication.
• Hypromellose-based film coating for moisture protection, identification and swallowability.

The critical development risks are not unusual for imatinib. They include blend segregation, high-dose content uniformity, lubricant sensitivity, tablet hardness, dissolution variability and coating performance. Over-lubrication can slow dissolution. Excessive compression force can reduce porosity and delay disintegration.

Wet granulation versus direct compression

Direct compression can reduce equipment, energy and processing costs, but its suitability depends on powder flow, segregation behavior and active loading. Wet granulation may provide better content uniformity and tablet robustness where the drug substance has poor flow or unfavorable bulk density.

Platform	Cost profile	Main advantage	Main risk
Direct compression	Lower	Fewer process steps	Segregation and flow variability
Dry granulation	Moderate	Improves density without water exposure	Granule over-compaction
Wet granulation	Higher	Strong content uniformity and robust tablets	Moisture, drying and scale-up complexity
Roller compaction	Moderate	Continuous or efficient dry processing	Variable ribbon density and dissolution

For a high-volume generic, a direct-compression or dry-granulation process is commercially attractive if it consistently meets dissolution and uniformity specifications.

What formulation patents could create commercial differentiation?

The most defensible formulation opportunities are dosage-form improvements that solve a defined clinical or operational problem.

Pediatric oral liquids

Imatinib is used in pediatric leukemia and other cancers, but tablets can be difficult for young patients or patients with swallowing limitations. An oral liquid, powder for reconstitution or ready-to-use suspension could improve dosing flexibility.

The excipient system would need to address:

• Taste masking.
• Chemical and microbiological stability.
• Sedimentation and redispersibility.
• Accurate dosing at low volumes.
• Compatibility with oral syringes and feeding tubes.
• Preservative effectiveness.
• Low sugar or sugar-free positioning.
• Acceptable viscosity for pediatric administration.

Potential technologies include ion-exchange resins, polymeric taste barriers, coated drug particles, microspheres and multiparticulate suspensions. The commercial value is higher when the formulation supports weight-based dosing without requiring tablet splitting or extemporaneous pharmacy compounding.

Dispersible and orally disintegrating tablets

A dispersible tablet could target patients unable to swallow conventional tablets. The excipient system would likely require a fast-disintegrating matrix, wetting agents and taste-masking technology.

Orally disintegrating tablets face a difficult balance. Imatinib has a bitter taste, and a simple superdisintegrant-based tablet may provide poor patient acceptance unless the drug particles are coated or otherwise taste masked.

Modified-release products

Once-daily or modified-release imatinib could reduce dosing frequency, but the opportunity is technically and commercially uncertain. Imatinib has an established once-daily regimen for many indications, and a modified-release product would need to show a clinically meaningful advantage rather than merely alter dissolution.

Potential technical approaches include hydrophilic matrix tablets, multiparticulate pellets, osmotic systems and gastroretentive platforms. These products would likely require a 505(b)(2) strategy rather than a simple ANDA if the proposed performance differs materially from the reference product.

What FDA pathways apply to new imatinib formulations?

ANDA pathway

A conventional immediate-release generic tablet generally uses the ANDA pathway. The applicant must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. The product should match the reference in strength, dosage form, route and active ingredient, subject to permitted differences in excipients and design.

505(b)(2) pathway

A novel oral liquid, modified-release dosage form or delivery system may fit the 505(b)(2) pathway. This route can rely partly on FDA findings for Gleevec while requiring additional data for the new formulation.

A 505(b)(2) program may be commercially attractive when it provides:

• Pediatric dosing flexibility.
• Better administration through feeding tubes.
• Reduced pill burden.
• Improved tolerability or adherence.
• A clinically differentiated release profile.
• An alternative for patients unable to swallow tablets.

The development cost and regulatory burden are higher than for an ANDA, but the product may obtain differentiated labeling and a period of regulatory exclusivity if the application qualifies.

What Orange Book status and Paragraph IV risks affect imatinib?

The Orange Book historically listed Gleevec patents and associated exclusivity information. For an established product with generic entry, the main commercial risk is no longer the expired core compound patent. It is the risk that a new entrant challenges any still-listed formulation or method-of-use patent through a Paragraph IV certification.

A Paragraph IV certification alleges that a listed patent is invalid, unenforceable or will not be infringed by the proposed generic. If the patent holder sues within the statutory period, FDA approval may be subject to a 30-month stay, subject to litigation developments and applicable statutory rules.

For standard imatinib tablets, the principal risk is competition among approved generics rather than a successful Paragraph IV challenge to a broad compound patent. For differentiated oral liquids, dispersible tablets or modified-release products, patent exposure may be more significant because a new formulation could overlap with later-filed formulation claims.

Which companies compete in the imatinib market?

The U.S. competitive field includes Novartis as the originator and generic manufacturers such as Teva, Sun Pharmaceutical, Cipla, Dr. Reddy's Laboratories and other regional suppliers, depending on market and product status.

Competitor type	Product strategy	Commercial position
Novartis	Gleevec brand	Originator, established clinical brand and global regulatory footprint
Large generic manufacturers	Standard tablets	Scale, procurement access and lower cost
Regional manufacturers	Tablets and selected alternative presentations	Local registration and distribution advantages
Specialty developers	Pediatric liquids or differentiated oral products	Higher potential margin and narrower market
API manufacturers	Imatinib mesylate drug substance	Supply-chain and cost leverage

The generic tablet segment is price competitive. A new entrant needs either a cost advantage, supply reliability, procurement access or a differentiated presentation.

What commercial opportunities exist for imatinib excipients?

Excipient suppliers

Excipient companies can target imatinib manufacturers with:

• Co-processed direct-compression systems.
• Low-peroxide and low-moisture excipients.
• Taste-masking polymers.
• Film-coating systems.
• Ready-to-use suspension vehicles.
• Preservative systems for oral liquids.
• Excipient packages qualified for feeding-tube administration.
• Continuous manufacturing formulations.

The value proposition should focus on shorter development timelines, lower process variability, improved dissolution and easier global registration.

Finished-dose manufacturers

The strongest opportunities are:

1. Low-cost, high-reliability tablets for public procurement.
2. Pediatric suspensions and dispersible tablets.
3. Products for patients with dysphagia or feeding tubes.
4. Regional products aligned with local dosing and packaging requirements.
5. Contract manufacturing for oncology portfolios.
6. Combination products pairing imatinib with supportive-care medicines, where legally and clinically justified.

Licensing and partnering

Licensing opportunities are more plausible for a differentiated dosage form than for another standard tablet. A specialty developer could license a pediatric liquid or taste-masked multiparticulate product to a generic manufacturer with oncology distribution. A formulation owner could provide technology, regulatory data and patent rights while the commercial partner supplies manufacturing capacity and market access.

No broad licensing structure is required for a conventional generic because the core active ingredient and standard tablet technology are widely available. Commercial arrangements are more likely to involve API supply, contract manufacturing, regional rights or formulation technology.

How strong is the patent estate for a new imatinib formulation?

The patent strength of a new imatinib product depends on the specificity and reproducibility of the claimed formulation.

Patent strategy	Relative strength	Reason
Broad claim to imatinib tablets	Low	Mature active ingredient and established generic products
Specific excipient ratio	Low to moderate	Vulnerable to design-around unless linked to unexpected performance
Taste-masked particles with defined coating parameters	Moderate	More difficult to replicate without using the claimed architecture
Pediatric suspension with stability and dosing claims	Moderate	Can protect a clinically useful product and manufacturing process
Novel modified-release system	Moderate to high	Stronger if it delivers a defined pharmacokinetic or clinical benefit
Manufacturing process with impurity control	Moderate	Useful where process conditions materially affect quality
Packaging and reconstitution system	Low to moderate	Potentially valuable but easy to design around

The strongest claims should connect composition to measurable performance, such as dissolution, suspension stability, redispersibility, taste reduction, particle-size distribution or pharmacokinetic behavior. Claims limited to routine excipient substitution are less likely to create durable barriers.

What geographic opportunities exist for imatinib products?

Imatinib demand remains linked to CML and GIST diagnosis, oncology reimbursement and access to targeted therapy. Geographic opportunities differ by product type.

Region	Opportunity
United States	Competitive generic tablets; differentiated pediatric and 505(b)(2) products
Europe	National tendering, reference-pricing pressure and formulation niches
India	Large generic manufacturing base, API and finished-dose exports
China	Domestic oncology demand and local registration opportunities
Latin America	Access-driven demand and regional generic supply
Africa and lower-income markets	Affordable, stable tablets and procurement reliability

For emerging markets, excipient selection should favor globally available materials with established compendial status. A formulation dependent on a single specialty excipient can create registration, supply and cost problems.

What generic launch scenarios exist for imatinib?

Standard tablet launch

This is the lowest-risk route but has the greatest price competition. Success depends on manufacturing cost, product availability and payer access.

Pediatric formulation launch

This has a smaller market but greater differentiation. The principal risks are taste, stability, dosing accuracy and the need for additional clinical or regulatory data.

Hospital and public-procurement launch

A manufacturer can compete through reliable supply, simple packaging, shelf-life performance and low landed cost. Excipient choices should support long shelf life under variable storage conditions.

Specialty 505(b)(2) launch

This can support higher pricing if the product offers a meaningful administration or adherence benefit. The program requires stronger clinical, bioavailability and intellectual-property planning than an ANDA.

Key Takeaways

• Imatinib is a mature small-molecule market dominated by generic tablets after U.S. exclusivity expired.
• Standard tablet excipient strategy should prioritize low cost, dissolution control, content uniformity and manufacturing robustness.
• The strongest formulation opportunity is a pediatric oral liquid, dispersible tablet or taste-masked multiparticulate product.
• A conventional tablet generally fits the ANDA pathway; differentiated dosage forms may require a 505(b)(2) application.
• Imatinib has no biosimilar risk because it is a small molecule, not a biologic.
• New patent value is most likely in defined taste-masking systems, pediatric formulations, modified release, manufacturing controls and reconstitution technology.
• Commercial opportunities are strongest where excipients solve administration, adherence, supply or stability problems rather than merely replace an existing tablet ingredient.
• Generic entry risk is high for undifferentiated tablets and lower for products with defensible formulation technology and regulatory differentiation.

FAQs About Imatinib Excipient and Formulation Strategy

Can imatinib tablets be made with different excipients from Gleevec?

Yes. An ANDA applicant may use different inactive ingredients if the product meets pharmaceutical equivalence, bioequivalence, quality and labeling requirements.

Is imatinib suitable for an oral suspension?

Yes, but the formulation requires control of bitterness, sedimentation, redispersibility, chemical stability, microbial quality and dose measurement.

Does imatinib have biosimilar competition?

No. Imatinib is a chemically synthesized small molecule. Competition proceeds through generic-drug pathways rather than biosimilar approval.

Would an imatinib oral liquid require a 505(b)(2) application?

Not necessarily. The pathway depends on the proposed product, reference product, formulation differences and FDA regulatory strategy. A materially differentiated liquid may be better suited to 505(b)(2) than to a conventional ANDA.

Which excipient property is most important for a generic imatinib tablet?

The highest-priority properties are reliable compressibility, low segregation risk, rapid and reproducible disintegration, controlled lubrication and consistent dissolution after scale-up.

References

1. U.S. Food and Drug Administration. (2016). FDA approves first generic versions of Gleevec.
2. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. Novartis Pharmaceuticals Corporation. (2023). Gleevec (imatinib mesylate) prescribing information.
4. U.S. Patent No. 5,521,184. (1996). Pyrimidine derivatives and processes for their preparation.
5. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application (ANDA) process.
6. U.S. Food and Drug Administration. (n.d.). 505(b)(2) applications.